eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination T
SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of eFFECTOR's tomivosertib (eFT508), an oral, small molecule inhibitor of MNK1/2, with Merck's anti-PD-1 therapy, KEYTRUDA® (